Abstract
Supplemental melatonin has been used to treat sleep onset insomnia in children with autism spectrum disorders (ASD), although the mechanism of action is uncertain. We assessed endogenous and supplemental melatonin profiles in relation to sleep in nine children with ASD. In endogenous samples, maximal melatonin concentration (C max) and time to peak concentration (T max) were comparable to those previously published in the literature for typically developing children, and dim light melatonin onsets were captured in the majority of children. In treatment samples (supplemental melatonin), melatonin parameters were also comparable to those previously published for typically developing children. Our findings support that children with ASD and insomnia responsive to low dose melatonin treatment have relatively normal profiles of endogenous and supplemental melatonin.
Similar content being viewed by others
References
Aldhous, M., Franey, C., Wright, J., & Arendt, J. (1985). Plasma concentrations of melatonin in man following oral absorption of different preparations. British Journal of Clinical Pharmacology, 19, 517–521.
American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: American Psychiatric Association.
Andersen, I. M., Kaczmarska, J., McGrew, S. G., & Malow, B. A. (2008). Melatonin for insomnia in children with autism spectrum disorders. Journal of Child Neurology, 23, 482–485.
Ardura, J., Gutierrez, R., Andres, J., & Agapito, T. (2003). Emergence and evolution of the circadian rhythm of melatonin in children. Hormone Research, 59, 66–72.
Benloucif, S., Burgess, H. J., Klerman, E. B., Lewy, A. J., Middleton, B., Murphy, P. J., et al. (2008). Measuring melatonin in humans. Journal of Clinical Sleep Medicine, 4, 66–69.
Burgess, H. J., & Fogg, L. F. (2008). Individual differences in the amount and timing of salivary melatonin secretion. PLoS ONE, 3, e3055.
Cai, G., Edelmann, L., Goldsmith, J. E., Cohen, N., Nakamine, A., Reichert, J. G., et al. (2008). Multiplex ligation-dependent probe amplification for genetic screening in autism spectrum disorders: Efficient identification of known microduplications and identification of a novel microduplication in ASMT. BMC Medical Genomics, 1, 50.
Carter, M. D., Calcutt, M. W., Malow, B. A., Rose, K. L., & Hachey, D. L. (2012). Quantitation of melatonin and n-acetylserotonin in human plasma by nanoflow LC-MS/MS and electrospray LC-MS/MS. Journal of Mass Spectrometry, 47, 277–285.
Centers for Disease Control and Prevention. (2012). Prevalence of autism spectrum disorders—autism and developmental disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveillance Summaries, 61, 1–19.
Couturier, J. L., Speechley, K. N., Steele, M., Norman, R., Stringer, B., & Nicolson, R. (2005). Parental perception of sleep problems in children of normal intelligence with pervasive developmental disorders: Prevalence, severity, and pattern. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 815–822.
DeMuro, R. L., Nafziger, A. N., Blask, D. E., Menhinick, A. M., & Bertino, J. S, Jr. (2000). The absolute bioavailability of oral melatonin. Journal of Clinical Pharmacology, 40, 781–784.
Di, W. L., Kadva, A., Johnston, A., & Silman, R. (1997). Variable bioavailability of oral melatonin. New England Journal of Medicine, 336, 1028–1029.
Fourtillan, J. B., Brisson, A. M., Gobin, P., Ingrand, I., Decourt, J. P., & Girault, J. (2000). Bioavailability of melatonin in humans after day-time administration of D(7) melatonin. Biopharmaceutics and Drug Disposition, 21, 15–22.
Gabriels, R. L., Cuccaro, M. L., Hill, D. E., Ivers, B. J., & Goldson, E. (2005). Repetitive behaviors in autism: Relationships with associated clinical features. Research in Developmental Disabilities, 26, 169–181.
Glickman, G. (2010). Circadian rhythms and sleep in children with autism. Neuroscience and Biobehavioral Reviews, 34, 755–768.
Goldman, S. E., Richdale, A. L., Clemons, T., & Malow, B. A. (2012). Parental sleep concerns in autism spectrum disorders: Variations from childhood to adolescence. Journal of Autism and Developmental Disorders, 42, 531–538.
Goldman, S. E., Surdyka, K., Cuevas, R., Adkins, K., Wang, L., & Malow, B. A. (2009). Defining the sleep phenotype in children with autism. Developmental Neuropsychology, 34, 560–573.
Iber, C., Ancoli-Israel, S, Jr, Chesson, A. L., & Quan, S. F. (2007). The AASM manual for the scoring of sleep and associated events: Rules, terminology and technical specifications. Westchester: American Academy of Sleep Medicine.
Jonsson, L., Ljunggren, E., Bremer, A., Pedersen, C., Landén, M., Thuresson, K., et al. (2010). Mutation screening of melatonin-related genes in patients with autism spectrum disorders. BMC Medical Genomics, 8(3), 10.
Kennaway, D. J. (2000). Melatonin and development: Physiology and pharmacology. Seminars in Perinatology, 24, 258–266.
Krakowiak, P., Goodlin-Jones, B., Hertz-Picciotto, I., Croen, L. A., & Hansen, R. L. (2008). Sleep problems in children with autism spectrum disorders, developmental delays, and typical development: A population-based study. Journal of Sleep Research, 17, 197–206.
Kulman, G., Lissoni, P., Rovelli, F., Roselli, M. G., Brivio, F., & Sequeri, P. (2000). Evidence of pineal endocrine hypofunction in autistic children. Neuroendocrinology Letters, 21, 31–34.
Leu, R. M., Beyderman, L., Botzolakis, E. J., Surdyka, K., Wang, L., & Malow, B. A. (2011). Relation of melatonin to sleep architecture in children with autism. Journal of Autism and Developmental Disorders, 41, 427–433.
Lewy, A. J. (1999). The dim light melatonin onset, melatonin assays and biological rhythm research in humans. Biological Signals and Receptors, 8, 79–83.
Lord, C., Risi, S., Lambrecht, L., Cook, E. H, Jr, Leventhal, B. L., DiLavore, P. C., et al. (2000). The autism diagnostic observation schedule-generic: A standard measure of social and communication deficits associated with the spectrum of autism. Journal of Autism and Developmental Disorders, 30, 205–223.
Malow, B., Adkins, K. W., McGrew, S. G., Wang, L., Goldman, S. E., Fawkes, D., et al. (2012). Melatonin for sleep in children with autism: A controlled trial examining dose, tolerability, and outcomes. Journal of Autism and Developmental Disorders, 42, 1729–1737. (author reply 1738).
Malow, B. A., Marzec, M. L., McGrew, S. G., Wang, L., Henderson, L. M., & Stone, W. L. (2006). Characterizing sleep in children with autism spectrum disorders: A multidimensional approach. Sleep, 29, 1563–1571.
Melke, J., Goubran Botros, H., Chaste, P., Betancur, C., Nygren, G., Anckarsater, H., et al. (2008). Abnormal melatonin synthesis in autism spectrum disorders. Molecular Psychiatry, 13, 90–98.
Nir, I., Meir, D., Zilber, N., Knobler, H., Hadjez, J., & Lerner, Y. (1995). Brief report: Circadian melatonin, thyroid-stimulating hormone, prolactin, and cortisol levels in serum of young adults with autism. Journal of Autism and Developmental Disorders, 25, 641–654.
Novakova, M., Paclt, I., Ptacek, R., Kuzelova, H., Hajek, I., & Sumova, A. (2011). Salivary melatonin rhythm as a marker of the circadian system in healthy children and those with attention-deficit/hyperactivity disorder. Chronobiology International, 28, 630–637.
Owens, J. A., Spirito, A., & McGuinn, M. (2000). The Children’s Sleep Habits Questionnaire (CSHQ): Psychometric properties of a survey instrument for school-aged children. Sleep, 23, 1043–1051.
Pandi-Perumal, S. R., Srinivasan, V., Maestroni, G. J., Cardinali, D. P., Poeggeler, B., & Hardeland, R. (2006). Melatonin: Nature’s most versatile biological signal? FEBS Journal, 273, 2813–2838.
Rossignol, D. A., & Frye, R. E. (2011). Melatonin in autism spectrum disorders: A systematic review and meta-analysis. Developmental Medicine and Child Neurology, 53, 783–792.
Salti, R., Galluzzi, F., Bindi, G., Perfetto, F., Tarquini, R., Halberg, F., et al. (2000). Nocturnal melatonin patterns in children. Journal of Clinical Endocrinology and Metabolism, 85, 2137–2144.
Schreck, K. A., Mulick, J. A., & Smith, A. F. (2004). Sleep problems as possible predictors of intensified symptoms of autism. Research in Developmental Disabilities, 25, 57–66.
Souders, M. C., Mason, T. B., Valladares, O., Bucan, M., Levy, S. E., Mandell, D. S., et al. (2009). Sleep behaviors and sleep quality in children with autism spectrum disorders. Sleep, 32, 1566–1578.
Toma, C., Rossi, M., Sousa, I., Blasi, F., Bacchelli, E., Alen, R., et al. (2007). Is ASMT a susceptibility gene for autism spectrum disorders? A replication study in European populations. Molecular Psychiatry, 12, 977–979.
Tordjman, S., Anderson, G. M., Pichard, N., Charbuy, H., & Touitou, Y. (2005). Nocturnal excretion of 6-sulphatoxymelatonin in children and adolescents with autistic disorder. Biological Psychiatry, 57, 134–138.
Waldhauser, F., Waldhauser, M., Lieberman, H. R., Deng, M. H., Lynch, H. J., & Wurtman, R. J. (1984). Bioavailability of oral melatonin in humans. Neuroendocrinology, 39, 307–313.
Wang, L., Li, J., Ruan, Y., Lu, T., Liu, C., Jia, M., et al. (2013). Sequencing ASMT identifies rare mutations in Chinese Han patients with autism. PLoS ONE, 8, e53727.
Acknowledgments
This work was supported by NICHD (RO1 HD59253), Vanderbilt General Clinical Research Center (M01 RR-00095 from the National Center for Research Resources, National Institutes of Health), and by the Vanderbilt University Kennedy Center (NICHD HD15052). Natrol® (Chatsworth, CA, USA), provided study drug but no other support. We acknowledge Ms. Kyla Surdyka and Ms. Meg Touvelle for their assistance with data entry and Dr. Susan McGrew for her assistance with medical evaluations. We are appreciative to the families who participated in this project.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Goldman, S.E., Adkins, K.W., Calcutt, M.W. et al. Melatonin in Children with Autism Spectrum Disorders: Endogenous and Pharmacokinetic Profiles in Relation to Sleep. J Autism Dev Disord 44, 2525–2535 (2014). https://doi.org/10.1007/s10803-014-2123-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10803-014-2123-9